Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;159(2):577-582.
doi: 10.1002/ijgo.14214. Epub 2022 Apr 22.

Reasons for satisfaction with the use of the 52-mg levonorgestrel intrauterine system

Montas Laporte  1 , Charles M Charles  1 , Sherly Metelus  1 , Rafael B Souza  1 , Alessandra Peloggia  1 , Luis Bahamondes  1
Affiliations

Reasons for satisfaction with the use of the 52-mg levonorgestrel intrauterine system

Montas Laporte et al. Int J Gynaecol Obstet. 2022 Nov.

Abstract

Objectives: To assess the reasons to use, reasons they liked, satisfaction with, and possibilities of recommendation to other women of the levonorgestrel 52-mg intrauterine system (LNG-IUS) by users.

Materials and methods: A cross-sectional study was conducted at the University of Campinas, Campinas, Brazil from January to July 2021. We enrolled users who came to the clinic, and we applied a pre-tested structured questionnaire with open-ended questions. We performed descriptive analyses of the variables, assessing the level of satisfaction with, and the reasons regarding the possibility of continuing to use, the IUS.

Results: Of the 517 enrolled women, 251 (48%) were aged 35 years or older (mean age 33.9 ± 9.0 years), 276 (53%) were white, 14 (3%) were adolescents, 155 (30%) were nulligravidas, and 307 (59.4%) reported experiencing amenorrhea in the last 90 days. Common reasons why women liked to use the LNG-IUS included both the reduction of menstrual bleeding (419 women; 81%) and dysmenorrhea (290 women; 56.1%). Nine out of 10 users (517 women; 91%) were satisfied with the method, and the majority would recommend it to other women.

Conclusion: We found a high satisfaction rate among LNG-IUS users mainly due to the reduction of both menstrual bleeding and dysmenorrhea.

Keywords: Brazil; levonorgestrel intrauterine system; long-acting reversible contraceptives; reasons for choice; satisfaction.

PubMed Disclaimer

References

REFERENCES

    1. Gormley R, Vickers B, Cheng B, Norman WV. Comparing options for females seeking permanent contraception in high resource countries: a systematic review. Reprod Health. 2021;18:154.
    1. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010;82:396-403.
    1. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:625-632.
    1. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol. 2016;55:1281-1284.
    1. Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110:1129-1136.

Substances

LinkOut - more resources